BellaSeno GmbH and the Fraunhofer Institute for Production Technology IPT have received at 1.4 million euros grant to develop additive-manufactured resorbable implants. The funding is coming from Germany´s Federal Ministry of Education and Research (BMBF) under the funding program KMU-innovativ.

“So far, the key steps in the additive manufacturing process had to be performed manually,” said Dr. Navid Khani, Head of R&D at BellaSeno. "The BMBF grant and the collaboration with Fraunhofer IPT will allow us to pursue a three- to four-fold increase of productivitiy for commercial-scale manufacturing driven by robotics and automation. As soon as we have fully established the new infrastructure, we will be able to create a cloud-based factory which can enable manufacturing at different locations and adapting the design by the push of the button. Such a fully scalable, automated, cloud-based additive manufacturing infrastructure for medical implants has never been established before."
 
BellaSeno and Fraunhofer IPT aim to develop a high-performance industrial scale-up process for its GMP-compliant manufacturing facilities, which include leading-edge features such as high-througput additive manufacturing based on the so-called no-touch approach to significantly improve the safety and sterility of medical implants.
 
Specifically, the collaboration partners plan to establish a fully automated, commercial-scale manufacturing platform supported by robotic systems and intelligent software which control the polymer-feeding, the implant handling, QC steps, labelling and recording traceability data. This will enable a constant 24-hour manufacturing flow covering all necessary process steps, while minimizing mistakes and optimizing the outcome of the production. With this approach, BellaSeno intends to significantly shorten development and manufacturing times and at the same time enhance the quality of its medical implants.
  
“The joint project combines BellaSeno’s extensive knowledge in 3D-printing high quality absorbable scaffolds and their ingenious Senella implant with Fraunhofer IPT’s vast experience in the development of fully automated cleanroom production facilities,” said Ferdinand Biermann, head of the business unit Life Sciences Engineering at the Fraunhofer IPT. “A freely moving, autonomous robot, fully networked processing units and an adaptive, service-oriented software structure allow repeatable and high quality manufacturing by maintaining full flexibility in the production process. Not only will the production site make it possible to bring products to market that immensely increase the patient’s quality of care, but it will also set a new benchmark for the automated production of medical implants.”
 
Senella is a patented porous scaffold made of absorbable Polycaprolactone (PCL) containing highly-specialized topological and design features, which act as recipients for injected fat tissue isolated with a standard liposuction procedure. The implant is designed to get absorbed over a span of two years and to provide a stable platform for the injected fat tissue to mature, adapt to its environment and stabilize. The clinical end result is a natural soft tissue – without remnants of foreign material. Senella therefore has the potential to alleviate the complications found in current breast reconstruction and augmentation approaches.